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Edited by Maurice MontalAbstract The CFTR, encoded by the gene mutated in cystic
ﬁbrosis (CF) patients, is responsible for cAMP dependent chlo-
ride transport in epithelia. Substances that activate CFTR have
been suggested as possible CF therapy. Most substances investi-
gated so far exert a dual eﬀect on the CFTR: low concentrations
stimulate CFTR, whereas higher concentrations inhibit CFTR.
Besides, the CFTR phosphorylation level determines the appar-
ent aﬃnity of the drug. We have studied the properties of geni-
stein, the well known CFTR potentiator, by measuring apical
membrane current on epithelia formed by cells stably transfected
with CFTR and stimulated with diﬀerent concentrations of CPT-
cAMP. We propose a quantitative model to describe the activa-
tory and inhibitory eﬀect of genistein, accounting also for the
cAMP dependent activation.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The cystic ﬁbrosis transmembrane conductance regulator
(CFTR) is an integral membrane polypeptide encoded by the
gene mutated in cystic ﬁbrosis (CF) patients. This protein be-
longs to the family of ATP-binding cassette (ABC) transport-
ers, but, unlike other members, functions as a chloride channel
(for a review see [1,2]). CFTR is activated by protein kinase A
(PKA)-mediated phosphorylation of multiple sites in its regu-
latory domain, and gated by binding (and probably hydrolysis)
of ATP at its two nucleotide binding domains (NBD1, NBD2).
Mutations into the CFTR gene impair chloride secretion in
epithelial cells thus causing severe dysfunction of various or-
gans [3].
Various CF-correlated mutations impair the chloride chan-
nel gating mechanisms (type III mutations; see www.genet.
sickkids.on.ca/cftr/), resulting in a strongly decreased epithelial
chloride secretion. As possible therapy for CF it has been sug-
gested the use of small organic molecules, CFTR potentiators,
that could activate these defective chloride channels [4,5].
Numerous CFTR potentiators, belonging to diﬀerent chemical
families, have been identiﬁed [6–12]. However, most of the
substances investigated so far exert a dual eﬀect on the CFTR:
low micromolar concentrations stimulate CFTR chloride cur-*Corresponding author. Fax: +30 0106475558.
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doi:10.1016/j.febslet.2005.06.026rents, whereas higher concentrations inhibit CFTR [13–17].
Besides, the CFTR phosphorylation level determines the
apparent aﬃnity of the drug [15,16]. To design and evaluate
new potential drugs, it is essential a quantitative characterisa-
tion of the eﬀects of potentiators on CFTR chloride transport.
The resulting set of parameters is expected to describe the
aﬃnity and potency of activation and inhibition of the candi-
date substance.
We have analysed the eﬀects of genistein, a well known
potentiator, on CFTR expressed in cells stimulated with dif-
ferent concentrations of CPTcAMP. We could formulate a
plausible hypothesis of the mechanism of action of this poten-
tiator, with a reduced number of parameters. The proposed
model could be used to evaluate the properties of a given
CFTR potentiator independently to the amount of cAMP
stimulation.2. Methods
Fisher Rat Thyroid (FRT) cells expressing wild type CFTR were
seeded at high density (5 · 105 cells/cm2) on Snapwell inserts (Costar,
Corning) with Coons Modiﬁed F12 containing 5% foetal bovine ser-
um, 2 mM L-glutamine, 50 U/ml penicillin and 50 lg/ml streptomycin
and 600 lg/ml of Zeocin, as previously described [18]. Apical and baso-
lateral media were replaced every 48 h. Transepithelial resistance was
daily measured with an epithelial voltohmmeter (Millipore-ERS, Mil-
lipore) using chopstick-like electrodes. After 4–7 days, FRT monolay-
ers developed a transepithelial resistance in the range of 2–4 kX cm2.
Experiments were done at days 7–9 after seeding.
Filters were mounted into an Ussing-like Vertical Diﬀusion Cham-
ber (Corning, Costar). The system was kept at 37 C and solutions
were bubbled with air. Basolateral membrane of FRT epithelia was
permeabilised with 250 lg/ml amphotericin B and a transepithelial
Cl gradient was applied as previously reported [18,19]. The apical
chamber was bathed with a low Cl containing solution (in mM): 65
NaCl, 65 Na gluconate, 1.5 KH2PO4, 2.7 KCl, 0.5 MgCl2, 2 CaCl2,
10 HEPES-Na and 10 glucose (pH 7.4). The basolateral chamber
was instead bathed with (in mM): 130 NaCl, 1.5 KH2PO4, 2.7 KCl,
0.5 MgCl2, 1 CaCl2, 10 HEPES-Na and 10 glucose (pH 7.4). Mem-
brane permeabilisation was monitored measuring the current response
to a 10 mV stimulus, to a stable condition of maximal conductance
after 30–40 min. Short-circuit current (Isc) was measured with a volt-
age-clamp ampliﬁer (DVC-1000, World Precision Instruments). CFTR
potentiators were added only to the apical side. Currents were always
measured in the presence of variable concentrations of 8-(4-chlorophe-
nylthio)-adenosine 3 0,5 0-cyclic monophosphate (CPTcAMP).
Responses to CPTcAMP were ﬁtted with a rectangular hyperbola
(see bellow), and normalised to the asymptotic value. Dose-response
to genistein was ﬁtted to the Isc elicited by CPTcAMP in the absence
of the CFTR potentiator. Data were ﬁtted using the Levenberg–Mar-
quardt algorithm, a form of non-linear, multivariate, least-squares ﬁt-
ting, as implemented in IgorPro (Wavemetrics).ation of European Biochemical Societies.
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CFTR is activated by protein kinase A (PKA)-mediated
phosphorylation of multiple sites in its R-domain, and by
the binding and probably hydrolysis of ATP at its two-nucle-
otide binding domains (NBD1, NBD2). From a systematic
analysis of R-domain mutants, it has been suggested that phos-
phorylation on diﬀerent sites would produce activation or inhi-
bition [1,20]. Hence, it imposes considerable diﬃculties on
applying a ﬁne control of phosphorylation in a wild type
CFTR preparation. We can suppose that, in the presence of
saturating concentrations of ATP, the CFTR activation would
proceed according to the following scheme.
PKA + CPTcAMP Activated PKA Activated CFTR?
Scheme 1
We assume that the initial step in the CFTR activation is the
PKA activation by the CPTcAMP by a pseudo ﬁrst-order
reaction that obeys the law of mass action. Then, activated
PKA is then transduced in an increase of chloride current as
a consequence of successive CFTR phosphorylation steps, by
a so-called black box function that properly relates the PKA
activation with the ﬁnal eﬀect on CFTR. The mathematical
formulation of the problem is as follows. The PKA-CPTcAMP
interaction with the above assumptions is represented by a
rectangular hyperbolic function between the activated PKA
and the concentration of CPTcAMP. If the relation between
the ﬁnal eﬀect, the magnitude of the chloride current, and
the ‘‘agonist’’ CPTcAMP is observed to be rectangular hyper-
bolic it indicates that the relation between the chloride current
and the activated PKA is linear or rectangular hyperbolic [21].
Fig. 1 shows data from 7 experiments where the Isc was mea-
sured at diﬀerent CPTcAMP concentrations, up to 500 lM.
Data was ﬁtted with the rectangular hyperbolic function:
I0 ¼ c½ KA þ c½  ; ð1ÞFig. 1. Normalised Isc elicited by diﬀerent concentrations of CPT-
cAMP. Data represent the average of normalised data obtained from
at least 7 experiments. Bars are the standard error of the mean. The
continuous line is the best ﬁt of data with Eq. (1).where I0 is the normalised Isc obtained at a given concentra-
tion of the nucleotide analogue, and [c] denotes the concentra-
tion of the applied agonist. We obtained an apparent
equilibrium constant of the CFTR activation by CPTcAMP,
KA, of 67.1 ± 6.4 lM. According to this hypothesis, we could
consider the cAMP analogue as the ligand to activate the
CFTR chloride channel, according to the simple scheme:
U A
KA
CPTcAMP
Scheme 2
where U represents the non phosphorylated state of CFTR (in
the presence of saturating concentration of ATP), and A is the
phosphorylated state in which the CFTR channel is activated.
Transition from state U to state A has an apparent equilibrium
constant of KA, and requires the presence of the cyclic nucleo-
tide.
Application of genistein to an epithelia on which CFTR has
been stimulated with CPTcAMP resulted on a bimodal re-
sponse, with an increase of chloride transport for low concen-
trations of genistein, and a decrease of the current when the
genistein concentration is increased (see Fig. 2). The most sim-
ple model to describe these kind of experiments is to assume
that there are two binding sites for genistein [16,17], one that
activates the CFTR and the second that inhibits the current.
The addition of genistein to CPTcAMP stimulated channels
increases the current, exceding I0, the maximum current elic-
ited by the CPTcAMP alone (described in Eq. (1)), by Iextra.
At the same time, the current is reduced as function of the
probability of the second inhibitory site is bound by the ligand,
Pblock. Hence, the current measured at a given concentration of
genistein and CPTcAMP can be expressed as:
I ¼ I0 þ Iextrað ÞP block;
I ¼ ½c½c þ KA þ I
ðmaxÞ
extra
½g
½g þ Kg
 
 K i½g þ K i ;
ð2Þ
where I0 is deﬁned as in Eq. (1), [g] is the concentration of
genistein, I ðmaxÞextra is the maximum extra current elicited by
genistein, Kg is the apparent equilibrium constant of geni-
stein binding at the activatory site, and Ki is the apparent
equilibrium constant of genistein binding to the inhibitory
site. Currents measured at given concentration of CPTcAMP
and variable concentration of genistein were normalised by
maximum asymptotic current expected in absence of the
CFTR-potentiator. When current data was ﬁtted with Eq.
(2), apparent equilibrium constant for both, the activatory
and the inhibitory sites, dramatically changed with the CPT-
cAMP concentration used to stimulate CFTR. Continuous
lines in Fig. 2A represents the ﬁtting of data with Eq. (2),
yielding the equilibrium constants described in the Fig. 2B,
where Kg varies from 180 to 30 lM, and Ki varies from
320 to 70 lM for 1 and 100 lM CPTcAMP concentration,
respectively. Continuous lines in Fig. 2B represents the best
ﬁtting of data with the empirical functions:
Kg cð Þ ¼ Kð1Þg þ Kð0Þg  Kð1Þg
 
 1 c½ 
c½  þ K cAMPð Þg
 !
;
K i cð Þ ¼ Kð1Þi þ Kð0Þi  Kð1Þi
 
 1 c½ 
c½  þ K cAMPð Þi
 !
;
ð3Þ
Fig. 2. Empirical ﬁtting of the eﬀect of genistein on the CFTR chloride
current measured at diﬀerent concentrations of CPTcAMP. (A) Data
points represent the mean values obtained from at least 3 experiments
at CPTcAMP concentrations between 1 and 100 lM, as indicated in
the ﬁgure. Bars are the standard deviation of data. Continuous lines
represent the ﬁt with Eq. (2). (B) Equilibrium constants for activation,
Kg and inhibition, Ki, resulting from the ﬁt of part (A). Continuous
lines represent the ﬁt with Eq. (3), yielding KðcAMPÞg ¼ 5.7 lM,
Kð0Þg ¼ 214 lM and Kð1Þg ¼ 2.9 lM for the activation process equilib-
rium constant, and KðcAMPÞi ¼ 1.7 lM, Kð0Þi ¼ 476 lM and
Kð1Þi ¼ 59.2 lM for the inhibition.
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constants for a concentration of CPTcAMP zero and inﬁnite,
respectively, and K(cAMP) is the apparent dependence of the
eﬀective equilibrium constant on CPTcAMP concentration.
This empirical formulation of the eﬀect of genistein on the
CFTR chloride currents measured at diﬀerent concentrations
of CPTcAMP needs 8 parameters to be described, and most
of them have not a clear physical meaning (Eq. (3)). Therefore,
we attempted to describe these experiments with a more formal
model, with physically interpretable parameters. Scheme 3 is
an alternative hypothesis proposed to ﬁt the experimental
data. There, we propose two main conditions, phosphorylation
and genistein binding, in the presence of saturating concentra-
tions on ATP. The phosphorylation or not of the CFTR is rep-
resented by states A and U, respectively, while binding or not
of the potentiator is represented by numbers 1 and 0, respec-
tively. A further state, inhibited CFTR channel is represented
by B. In this model, we assumed that any state diﬀerent to the
inhibited state B, or to the no-phosphorylated and genistein-
free state U0 is a conductive state. Consequently, the chloridecurrent is proportional to the probability of occupancy of
states A0, A1 and U1. Equilibrium constants for the transitions
are indicated in the scheme.
U0 A0
U1 A1
B
CPTcAMP
CPTcAMP
gen gen
gen
Kc,0
Kc,1
Kd,0
Kd,1
Kb
Scheme 3
On the other hand, the current measured is proportional to
the probability of occupancy of each conductive state (A0, A1,
and U1), and to the relative conductance for each state (single
channel conductance times the open channel probability).
Therefore, the observed current is deﬁned as I = PA0fA0 +
PA1fA1 + PU1fU1, where Pn is the occupancy probability for
each state, and fn is the relative conductance for each state.
A current data was normalised to the maximum expected value
for a high CPTcAMP concentration, in the absence of geni-
stein (and in saturating concentrations of ATP), the relative
conductance of state A0 is deﬁned as fA0 = 1.
We did several attempts to ﬁt the experimental data with
model presented in Scheme 3 and to few variations of this
model. As described, Scheme 3 indicates that inhibition of
the channel, state B, can proceed from any state, phosphor-
ylated or not phosphorylated, or with or without genistein
bound to an activatory state. We tested the ﬁtting of data
with models in which state B could proceed only from open
states (AO, A1 and U1), from phosphorylated states (AO
and A1), or from genistein-bound states (A1 and U1). Data
resulting from Fig. 1 was used as a guess value for the con-
stant Kc,0, and therefore conditioned the system to look for
parameters that do not change this value signiﬁcantly. Inter-
estingly, for the model in Scheme 3 and for its variations,
the best ﬁt was obtained for Kd,0ﬁ1 and Kc,1ﬁ 0. This
indicates that to ﬁt data we have to suppose that state U1
cannot occur. This interpretation is compatible with the
observation that the activation of the CFTR chloride chan-
nel by genistein and other CFTR potentiators occurs only in
phosphorylated channels [2,14,22]. Similar results were ob-
tained also if we assumed that state U1 is not conductive.
A second interesting observation is that the best ﬁt was ob-
tained for a model where the inhibited state proceeds only
from state A1. It suggests that binding of genistein to the
putative inhibitory state would occur only when CFTR is
phosphorylated and a genistein is already bound in the puta-
tive activatory site. Consequently, the system is reduced to
the following scheme:
U0 A0 A1 B
CPTcAMP gengen
Kc Kd Ki
Scheme 4
where U0 is the non-active state, A0 and A1 represents the
CFTR conductive states, and B is the inhibited state. Experi-
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applied after stimulation of CFTR at diﬀerent CPTcAMP con-
centrations were ﬁtted with the steady state solution for the
system describing Scheme 4:
I ¼ c½  fA1 g½  þ Kdð ÞK i
KcKdK i þ c½  g½ 2 þ g½ K i þ KdK i
 
.
ð4Þ
Normalised current data were bi-variable ﬁtted as a function
of the CPTcAMP and genistein concentrations. Continuous
lines in Fig. 3 represent the best ﬁt to with Eq. (4), yielding
the equilibrium constants Kc = 73.2 ± 1.6 lM, Kd = 6.2 ±
0.3 lM, and Ki = 139.1 ± 5.6 lM, and a relative conductance
for the A1 state fA1 = 1.12 ± 0.02. A value of fA1 > 1 is consis-
tent with a higher open channel probability measured in the
presence of genistein [14,22].
Fitting data with the sequencial model described in Scheme 4
resulted on a minor improvement on the goodness of the ﬁt-
ting, yielding a v2 = 0.167, compared with a v2 = 0.144 ob-
tained from the ﬁt of data with the two-sites model.
However, we consider that the sequencial binding model have
two advantages. The system can be described with only four
parameters, in contrast to the two-sites model that requires
eigth parameters to be described. Moreover, while the descrip-
tion of two-binding sites model is based on empirical parame-
ters without a clear physical meaning (in particular the two
pairs of K(0) and K(1) constants), the parameters that outline
the sequencial binding scheme have a direct physical interpre-
tation, that could be used to describe molecular models of the
mechanism of action of CFTR potentiators.
We could speculate a physical interpretation of this kinetic
model on the basis of some experimental and modelling data.
There are good evidences that, in the presence of saturating
concentrations of ATP, when CFTR is phosphorylated, the
chloride channel is activated upon the dimerisation of the
NBDs [23–25]. On the other hand, several evidences stronglyFig. 3. Fitting of the eﬀect of genistein on the CFTR chloride current
measured at diﬀerent concentrations of CPTcAMP. Data points
represent the mean values obtained from al least 3 experiments at
CPTcAMP concentrations between 1 and 100 lM, as indicated in the
ﬁgure. Bars are the standard deviation of data. Continuous lines
represents the multivariate ﬁt of normalised current as a function of
CPTcAMP and genistein concentrations with Eq. (4).suggest that some CFTR potentiators, as genistein, proba-
bly exert their action by interacting with the NBDs
[11,13,14,16,25]. Experimental data [25] and molecular simula-
tions [16] supports the idea that CFTR potentiators bind on
the NBD1-NBD2 interface, probably stabilising the dimerisa-
tion of these domains, and consequently the activated state of
the CFTR chloride channel. Binding of genistein at the NBDs
dimer interface requires a contact of the potentiator with both
NBDs. According to our molecular model of CFTR potenti-
ators interaction with the NBDs, the binding of genistein to
NBD1, with more hydrogen bonds and higher surface contact,
would be tighter than interaction with NBD2. Therefore, we
could speculate that genistein binds to NBD1 before dimerisa-
tion, and when bound, it stabilises this active conformation. At
higher potentiator concentration, genistein would bind also the
NBD2 before dimerisation, rendering impossible the interac-
tion between NBD1 and NBD2 by steric constrictions, as both
NBDs would have a bound genistein. Further experiments,
using other CFTR potentiators, would be necessary to more
validate this model.
In conclusion, we have presented a quantitative model that
describes the activation and inhibition of chloride current by
a CFTR potentiator. The advantage of this model is that
can be described by only four parameters, accounting also
the inﬂuence of the phosphorylation level as a consequence
of the stimulation of CFTR by a permeable cAMP analogue.
This data may be used to compare the properties of diﬀerent
CFTR potentiators to have a consistent framework for drug
design purposes.
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